Potential indications for liver transplant in Child–Pugh A and Model for End‐stage Liver Disease exception for hepatocellular carcinoma in Japan

Authors:

Abstract
Aim: In 2019, expanded criteria for hepatocellular carcinoma (HCC), known as 5‐5‐500 (size ≤5 cm, number ≤5, alpha‐fetoprotein ≤500 ng/mL), as well as Model for End‐stage Liver Disease (MELD) exception, were implemented in Japan. In the present study, we evaluated liver transplantation indications and the Japanese allocation policy for HCC.Methods: Adults with HCC were evaluated between January 2013 and December 2017 in a multicenter study in Japan. The patients were aged ≤65 years, in line with the limits of Japanese transplant center limits.Results: HCC patients (n = 289) were classified as Child–Pugh A (74%), B (18%), or C (8%). Of these, 178 (62%) and 185 (64%) met the Milan and 5‐5‐500 criteria, respectively. The respective 1‐ and 5‐year overall survival rates of patients who met the criteria were 100% and 88.1% in Child–Pugh A, 91.7% and 30.6% in B, and 72.9% and 0% in C without access to liver transplantation. For Child–Pugh A patients, we developed a risk score using the Child–Pugh score, des‐gamma‐carboxy prothrombin, tumor‐node‐metastasis stage grade, as well as albumin‐bilirubin and albumin‐bilirubin tumor‐node‐metastasis stage , which predicted worse prognosis. Additionally, we showed the characteristics of patients who achieved MELD exception points high enough to receive an organ: survival at least 2 years after waitlist registration, relatively good liver functional reserve, and sufficient tumor control with multiple treatments.Conclusions: High‐risk patients, identified by our scoring system and albumin‐bilirubin tumor‐node‐metastasis stage ≥2 in Child–Pugh A, should be considered for liver transplantation eligibility. The allocation policy for HCC should be revised based on precise evaluations on a regular basis.
Funding Information
  • Japan Society for the Promotion of Science

This publication has 27 references indexed in Scilit: